Cystic Fibrosis announces positive results on clinical trials

Hugh Farr (photo)

Executive Director

Local CF Chapter

Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 – an Oral Compound to Treat CF

The Cystic Fibrosis Foundation announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.

Patients who took the drug for 14 days showed significant improvements in several key indicators of cystic fibrosis, including lung function, nasal potential difference measurements and sweat chloride levels. The findings suggest that VX-770 improves function of what is known as the faulty CFTR protein. This early data is promising and could have important implications for studies of other drugs in development.

For more of the story, click the link.

http://www.cff.org/aboutCFFoundation/PressRoom/2008PressReleases/index.cfm?ID=8475&blnShowBack=False&idContentType=3617&IDCT=3617